NASDAQ · ISRG
Intuitive Surgical, Inc.
$448.76+$4.58 (+1.03%)
Intuitive Surgical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.69% below the high.
Loading market information…
NYSE · EW · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Edwards Lifesciences Corporation’s quoted price sits in the upper half of its reported 52-week range, 1.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Edwards Lifesciences Corporation’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of $0.74. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Edwards Lifesciences Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | Apr 23, 2025 | $0.64+7.38% vs estimate | $1.41B+0.87% vs estimate |
|---|
| Q4 2024 | Feb 11, 2025 | $0.59+7.08% vs estimate | $1.39B+1.98% vs estimate |
|---|
| Q3 2024 | Oct 24, 2024 | $0.67+0.75% vs estimate | $1.35B-12.31% vs estimate |
|---|
THE ANALYST VIEW
49 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 8 contributors · Median target $102.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$448.76+$4.58 (+1.03%)
Intuitive Surgical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.69% below the high.
€42.89+€0.30 (+0.7%)
Siemens Healthineers AG’s quoted price sits in the upper half of its reported 52-week range, 13.7% below the high.
¥2,388+¥19 (+0.8%)
Terumo Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.19% below the high.
$321.97+$3.66 (+1.15%)
Penumbra, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.16% below the high.
¥1,747-¥22 (-1.24%)
Olympus Corporation’s quoted price sits in the lower half of its reported 52-week range, 20.97% below the high.
SEK 273.40+SEK 1.50 (+0.55%)
Getinge AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.18% below the high.
CN¥275.34+CN¥2.55 (+0.93%)
APT Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.35% below the high.
$81.25+$0.59 (+0.73%)
LivaNova PLC’s quoted price sits in the upper half of its reported 52-week range, 5.26% below the high.
